REQUEST A DEMO
Total
USD $0.00
Search more companies

Curacle Co.,Ltd. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Curacle Co.,Ltd. Profile Updated: November 22, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

The company is a Korea-based company primarily engaged in the development of therapeutics for intractable vascular and metabolic diseases. The Company researches and develops synthetic drugs CU06-RE, CU01, and natural drug CU03 as new drugs for intractable vascular diseases. The Company's drugs are used for diabetic macular edema (DME), diabetic nephropathy (DN), and wet age-related macular degeneration (wet AMD). In addition, the Company uses the SOLVADYS platform technology, a platform technology for the development of vascular endothelial dysfunction blockers. The Company was established on May 12, 2016. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on July 22, 2021.

Headquarters
23-1, Hyoryeong-Ro, Seocho-Gu
Seoul; Seoul;

Contact Details: Purchase the Curacle Co.,Ltd. report to view the information.

Website: http://www.curacle.com

Basic Information
Total Employees:
Purchase the Curacle Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Curacle Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Curacle Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Curacle Co.,Ltd. report to view the information.
Incorporation Date:
May 12, 2016
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Subsidiaries
㈜큐라클
Company Performance
Financial values in the chart are available after Curacle Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-92.6%
Total operating revenue
-92.11%
Operating profit (EBIT)
-153.37%
EBITDA
-173.04%
Net Profit (Loss) for the Period
-175.69%
Total assets
-15.06%
Total equity
-29.5%
Operating Profit Margin (ROS)
-1341.91%
Net Profit Margin
-1293.24%
Return on Equity (ROE)
-13.8%
Debt to Equity Ratio
21.24%
Quick Ratio
-50.02%
Cash Ratio
-6.44%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?